好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Expected Centiloid Values for Patients with Positive Visual Reads of Amyloid PET Scans
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
13-005
To determine the expected range of Centiloid (CL) values from amyloid PET scans assessed as positive by visual reads based on published literature and baseline clinical trial results.

While amyloid PET scans can be assessed by visual reads, some clinical trials now use a CL cut-off. The CL scale was developed to standardize comparison across PET tracers, with the intent to approximate a value of 0 for amyloid negativity and an approximate value of 100 for mild to moderate dementia.
The literature was reviewed to assess the range of CL values that might be expected for scans that were amyloid positive by visual read. For each PET ligand, a CL value can be calculated from the standard uptake value ratio (SUVr) using published equations.
Based on published results, for patients with autopsy findings showing an early amyloid stage, CL threshold values ranged from 7.4 to 12.2. Across 13 studies using different PET ligands, threshold values for amyloid positivity ranged from 12.4 CL to 40 CL. In the IDEAS study, visually positive PET scans (n=6332) had CL values ranging from approximately -40 CL to approximately 275 CL. In the phase 3 CLARITY study of lecanemab (n=1734), CL values at baseline ranged from -17 to 213.2 for visually positive PET scans. ALTITUDE-AD is an ongoing phase 2 study of sabirnetug that has completed enrollment of 542 participants with MCI or mild dementia due to AD. In this study, preliminary baseline CL values ranged from -20.37 to 220.32.
The actual range of CL values for individuals with MCI or mild dementia with visually positive amyloid scans is likely wider than 0 to 100. The preliminary baseline CL values from the ALTITUDE-AD study are consistent with the published literature. Overreliance on CL cut-offs may bias against the detection of clinically relevant early amyloid deposition. 
Authors/Disclosures
Eric R. Siemers, MD (Siemers Integration LLC)
PRESENTER 		Dr. Siemers has received personal compensation for serving as an employee of Acumen Pharmaceuticals. The institution of Dr. Siemers has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for Vaccinex Pharmceuticals. The institution of Dr. Siemers has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for Gates Ventures LLC. Dr. Siemers has or had stock in Acumen Pharmaceuticals.Dr. Siemers has or had stock in Ell Lilly and Company.Dr. Siemers has received personal compensation in the range of $0-$499 for serving as a study section reviewer with National Institutes of Health. Dr. Siemers has a non-compensated relationship as a Volunteer with Alzheimer's Association that is relevant to AAN interests or activities.
Maddelyn Hyland, MPH Miss Hyland has received personal compensation for serving as an employee of Acumen Pharmaceuticals.
David Scott, PhD Mr. Scott has nothing to disclose.
Todd Feaster, PsyD Dr. feaster has received personal compensation for serving as an employee of Acumen Pharmaceuticals. Dr. feaster has stock in Acumen Pharmaceuticals.
Gopalan Sethuraman Dr. Sethuraman has received personal compensation for serving as an employee of Acumen Pharmaceuticals. Dr. Sethuraman has stock in Acumen Pharmaceuticals.